Saudi Journal of Gastroenterology

REVIEW ARTICLE
Year
: 2010  |  Volume : 16  |  Issue : 2  |  Page : 66--74

Gastrointestinal and hepatic manifestations of primary immune deficiency diseases


Saleh Z Al-Muhsen 
 Prince Naif Center for Immunology Research, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Correspondence Address:
Saleh Z Al-Muhsen
Department of Pediatrics, King Khaled University Hospital, King Saud University, King Faisal Specialist Hospital and Research Center, P.O. Box 2925, Riyadh 11461
Saudi Arabia

Abstract

Primary immune deficiency diseases (PIDs) are a heterogeneous group of inherited diseases characterized by variable genetic immune defects, conferring susceptibility to recurrent infections. They have a vast array of manifestations some of which involve the gastrointestinal and hepatobiliary systems. These complications can be the consequence of five different factors, namely, infection, autoimmune process, unregulated inflammation, malignancies and complications of therapeutic intervention. They may precede the PID diagnosis and, once developed, they pose high risk of morbidity. Untrained clinicians may treat these manifestations only at the level of their presentation, leaving the PIDs dangerously undiagnosed. In fact, early diagnosis of PIDs and accompanied gastrointestinal and hepatic complications clearly require appropriate treatment, and in-turn lead to an improved quality of life for the patient. To improve the awareness of gastroenterologists and related health care providers about these diseases, we have reviewed herein the complications of different PIDs focusing on gastrointestinal and hepatic manifestation.



How to cite this article:
Al-Muhsen SZ. Gastrointestinal and hepatic manifestations of primary immune deficiency diseases.Saudi J Gastroenterol 2010;16:66-74


How to cite this URL:
Al-Muhsen SZ. Gastrointestinal and hepatic manifestations of primary immune deficiency diseases. Saudi J Gastroenterol [serial online] 2010 [cited 2019 Dec 15 ];16:66-74
Available from: http://www.saudijgastro.com/text.asp?2010/16/2/66/61230


Full Text

Primary immune deficiency diseases (PIDs) are a heterogeneous group of inherited disorders with unique genetic defects in the immune system. They confer susceptibility to recurrent infections with virulent and non-virulent organisms. In addition to infections, they have a wide spectrum of clinical manifestations including autoimmune diseases, unregulated inflammation and predisposition to malignancies. [1],[2],[3],[4] PIDs are generally considered uncommon diseases; however, recent data from the Middle East, including Saudi Arabia, indicated that PIDs are 10-20 times more common than worldwide reported figures, [5],[6],[7],[8] probably secondary to high incidence of consanguinity, reaching up to 50% in some countries. [9],[10],[11],[12],[13]

Currently, more than 140 distinct genes have been identified, the abnormalities of which account for more than 200 different clinical phenotypes of PID. [2] Since this field is continuously revolutionized with unforeseen discoveries of novel PIDs and the characterization of their molecular defects, The International Union of Immunological Societies (IUIS) has recently updated the classification of PIDs [Table 1]

It is important for clinicians to be aware of the various manifestations of PIDs. Early recognition and diagnosis is vital in improving the quality of life and wellbeing of these patients.

 General Concepts



The most common manifestation of PIDs is usually respiratory in nature; however, with advances in diagnostic tools, appropriate antimicrobial therapy and intravenous immunoglobulin replacement therapy, respiratory infections have been fairly controlled. The next system commonly affected in PIDs is the gastrointestinal (GI) system, serving as a primary barrier to infections and considered the largest immune organ of the body. [14]

The GI complications of PIDs can present in five different forms: (1) infection throughout the GI0 tract or hepatobiliary system such as giardiasis in humoral immune dysfunction; cytomegalovirus colitis and hepatitis in severe T cell dysfunction as well as hepatic abscess in phagocytic defect. (2) Autoimmune phenomena as seen in autoimmune hepatitis and enteropathy associated with some PIDs. (3) Unregulated inflammatory conditions such as granulomatous colitis in CGD. (4) Malignancies involving the GI0 tract and hepatobiliary system.(5) GI0 and hepatic complications secondary to therapeutic intervention, for example, liver or gut graft-versus-host-disease and veno-occlusive disease post hematopoietic stem cell transplantation in certain PIDs. Nevertheless, addressing the variable manifestations of PIDs is beyond the scope of this review. We will therefore focus on a few examples of PID diseases commonly present with GI0 and hepatic manifestation, which might be the initial presentation of the disease rather than as part of the constellation of symptoms PIDs are known for. [15] Further examples of PIDs presenting with GI and hepatic manifestation are summarized in [Table 1].

 Chronic Granulomatous Disease



Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by a genetic defect in one of the components of NADPH oxidase of the phagocytic cells. This important complex is responsible for the generation of superoxide and is involved in combating catalase producing organisms such as many bacteria and fungi. [16],[17],[18],[19] Five genetic mutations involving the phagocytic oxidase system have been identified so far. The most common is an X-linked recessive defect in gP91phox, while three other autosomal recessive (AR) defects were reported in P22phox, P47phox and P67phox components of the NADPH oxidase system. [20],[21],[22],[23],[24],[25] A novel mutation in NCF4, the gene encoding P40phox, has also recently been reported in a boy who presented with granulomatous colitis, delineating the fourth AR form of CGD. [26] In addition to susceptibility to infections, CGD patients are prone to develop noninfectious complications characterized by unregulated inflammation such as granulomatous colitis, chorioretinal lesions and lupus-like disease. [27],[28],[29]

Gastrointestinal manifestations in CGD

GI manifestation is commonly encountered among CGD patients and might even precede the CGD diagnosis. [30] It usually arises from an abnormal inflammatory response leading to exuberant granuloma formation. In a study of 140 patients, GI manifestation was recorded in 46 patients (32.8%). [30] Abdominal pain, vomiting, diarrhea and weight loss, although nonspecific, were common GI symptoms among these CGD patients. [30],[31],[32] Moreover, we have observed that 8 (15%) of 55 CGD patients had colitis and/or GI obstruction (unpublished data). [33]

Proximal gastrointestinal tract manifestations

Granulomatous stomatitis, oral ulcers and dental abscesses are often found in these children. [30],[32] Oral candidiasis has also been documented. [34] Affected individuals may present with granulomatous inflammation causing obstruction and stricture formation throughout the entire GI tract. Therefore, it is not unusual for these patients to present with obstructive upper GI symptoms such as dysphagia, dysmotility, delayed emptying and vomiting. [31],[32] Other gastric complications include eosinophilic gastritis and abscesses have been rarely reported. [35]

Intestine and colon manifestations

Granulomatous colitis is prevalent among CGD patients, especially X-linked variant CGD. [29] The endoscopic finding is similar to inflammatory bowel disease (IBD), particularly, Crohn's disease (CD) characterized by transmural patchy inflammatory "skip lesions" with intact segments between the diseased ones [Figure 1]. These inflammatory lesions might cause obstruction, stenosis and fistula. [36] The difference between CD and CGD colitis lies in the histopathology of the granuloma formation. CGD colitis is characterized by sharply defined aggregates of epithelioid histiocytes surrounded by a cuff of dense lymphocytic inflammation [Figure 2]. In CD, granulomata are poorly defined. [30] One group claims that the main difference lies in the presence of pigment-laden macrophages within the lamina propria. [36] Of note, the inflammatory infiltrates of this form of colitis were mainly eosinophils and macrophages. There is also an increased expression of HLA-DR in the epithelium and vascular endothelium. [37] Nevertheless, the presentation is very similar to that of IBD, more specifically, CD, to an extent that it fulfills the Lennard-Jones criteria for CD. Furthermore, a subset of CGD patients may have IBD symptoms as their initial presentation. [30],[32],[34]

Distal gastrointestinal tract manifestations

Fistulae-in-ano is common probably due to the high bacterial load in the perianal area resulting from ineffective clearance of bacteria in CGD patients. It usually develops following infection of the perianal glands or granulomatous inflammation arising from the rectum. Steroids and interferon-g have been shown to be effective in controlling the GI granulomatous inflammation among CGD patients, and may reduce the thickening and relieve the obstruction. [30],[32] However, large scale prospective studies are required to validate their safety and efficacy.

Growth delay

Another consequence of chronic GI inflammation among children with CGD is growth delay. [30] In a large CGD cohort with GI complication, 32% had at least 1 height measurement below the fifth percentile and 22% had at least 1 weight measurement below the fifth percentile during their study period. Furthermore, CGD patients with GI involvement are more prone to suffer growth delay compared to those who are unaffected. [30]

Hepatobiliary manifestations in CGD

Transient elevation of liver enzymes is a common incidental finding in CGD. [38] One of the contributing factors is recurrent liver abscesses, which are frequently encountered among CGD patients. [29] Liver abscesses were reported in 25% to 45% of CGD patients, and were correlated with high rate of mortality reaching up to 27% in some studies despite appropriate antimicrobial therapies. [29],[31] According to the national US registry, Staphylococcus aureus, Pseudomonas aeruginosa, and Burkholderia cepacia were the most common pathogens isolated from these abscesses. Other infections with Serratia, Aspergillus, Candida and Mycobacteria were also encountered. [29],[38],[39] Typically, these abscesses relapse frequently, but at a new location in the liver. [38] They are dense, fibrotic, caseous, difficult to drain and almost always require surgery.

The elevation in liver enzymes cannot be attributed only to infections. Hussain et al, reported 29 CGD patients who developed drug-related hepatotoxicity. [38] Further studies are needed to explore the substantial risk of drug hepatotoxicity in CGD patients, as a majority of CGD patients will need long-term antibiotic and antifungal prophylactic therapies. [39],[40],[41],[42]

In summary, CGD has variable GI manifestations. In addition to infections, exuberant granulomatous inflammation may occur anywhere along the GI tract, which is very similar to CD in presentation. In certain circumstances this might be complicated with obstruction. These patients will be burdened with abdominal pain, nausea, vomiting, diarrhea and constipation. Eventually, GI complications lead to growth delay and failure to thrive. Chronic liver abscess is a significant risk for morbidity in CGD that warrants long-term antibiotic therapy and surgical intervention in some instances. Another complication that should be dealt with in these patients is liver injury due to drug-induced hepatitis.

CGD was formerly associated with high mortality but current practice of antimicrobial, IFN-g prophylaxis, aggressive surgery and early hematopoietic stem cell transplantation or gene therapy have improved the outcome substantially. [39],[40],[41],[42],[43],[44],[45],[46],[47]

 Common Variable Immunodeficiency



Common variable immunodeficiency (CVID) is the second most prevalent PID. It is characterized by dysfunction of the humoral immunity with low B lymphocytes, hypogammaglobulinemia and/or impaired antibody response to infection and vaccination. Affected individuals are therefore vulnerable to recurrent respiratory infections, chronic diarrhea and autoimmune manifestations. In fact, the immune defect is not limited to immunity cells; there is a clear crucial role for T cell defect in CVID as well. Moreover, most GI manifestation is probably related to T cell dysfunction explaining the poor response to intravenous immunoglobulin (IVIG) alone. [48],[49] Despite its prevalence and the plethora of literature on CVID, it is not fully elucidated at the molecular level. The underlying genetic defects have been explored in only a small subset of CVID. Mutations in three genes, TACI (transmembrane activator and calcium-modulator [CAML] and cyclophilin ligand Interactor), [50] ICOS (an inducible costimulator on activated T cells) [51] and CD19 genes, were found to cause only 10% of CVID cases. [52]

Gastrointestinal manifestations

Several studies showed that the prevalence of GI manifestation in CVID is quiet significant, ranging from 20% to 50%. [48],[53],[54] Noteworthy to mention is that these GI complications pose high morbidity and come second only to respiratory complications.

Proximal gastrointestinal tract manifestations

Although the oral cavity and esophagus are not commonly affected in CVID, the prolonged antibiotic administration, with accompanying neutropenia, predispose to fungal infections, especially esophageal candidiasis. [49],[55]

Atrophic gastritis and achlorhydria are common ailments, reported in about 50% of the cases among CVID patients. [48],[53] Pathologic studies revealed mild to moderate infiltration of lymphomononuclear cells in the lamina propria, lack of plasma cells and increased apoptosis. [48],[49],[55] Reduced serum gastrin levels and pernicious anemia-like syndrome might develop eventually. [48],[53] CVID disease significantly increases the risk for gastric carcinoma that might reach up to 50-fold. Concomitant Helicobacter pylori infection increases this risk substantially. [48],[56]

Small intestine manifestations

Chronic diarrhea is the most common GI manifestation, and may be the solo presentation of CVID. Several factors contribute to chronic diarrhea, including: Celiac sprue-like disorder, Giardia infection, bacterial overgrowth and, rarely, small bowel lymphoma. [48] Histopathologic studies consistently report villous blunting; however, there is absence of plasma cell infiltration.

Giardia lamblia is a prominent pathogen in the small bowel disease among CVID patients, resulting in abdominal cramps, bloating and watery diarrhea. [48] Despite empiric therapy with metronidazole, diarrhea is minimally resolved due to high recurrence of infection.

Autoimmune enteropathy is another distinct CVID manifestation with auto-antibodies directed against the enterocyte, thus further contributing to chronic diarrhea. [48],[49]

Moreover, nodular lymphoid hyperplasia (NLH) resulting from failure of B cell follicle formation, occurs commonly in CVID. It manifests as multiple polyps or nodules in the small intestine, but could also be seen in the stomach and colon. [49],[56],[57]

Large intestine manifestations

IBD is frequently encountered in CVID. Colitis due to CVID is distinct from other forms of colitis. Nevertheless, it mimics ulcerative crypt destructive colitis with regard to certain features. On examining histopathological biopsies, one can usually observe an increase in lymphocyte and macrophage inflammatory infiltration as well as overexpression of apoptosis; however, granulomas and giant cells are usually absent [Figure 3]a and b. [48],[55] The underlying mechanisms may involve T cell defect and autoimmune phenomenon; therefore, IVIG alone does not control the symptoms. Steroids and immunosuppressive therapies are often used with reasonable response.

Malignancy

CVID has substantial risk of GI malignancies. There is a 50-fold higher risk of gastric adenocarcinoma among CVID patients. [58] Contributing factors include achlorhydria, intestinal metaplasia and pernicious anemia. Early monitoring with endoscopies is therefore essential, especially for patients manifesting with constitutional symptoms such as weight loss or anorexia. Moreover, risk for B cell immunophenotype lymphoma triggered by Epstein-Barr virus is 30 times higher in CVID patients as well. [48],[58],[59]

 Hyper IgM Syndrome



Hyper IgM (HIGM) syndrome is a rare primary immunodeficiency disease caused by impaired Immunoglobulin class switch recombination (CSR) and characterized by normal or high IgM along with low or undetectable immunoglobulin subtypes including IgG, IgA and IgE. [60] Different molecular causes have been described that result in different HIGM phenotypes including defects of CD40 ligand (CD40L), CD40, nuclear factor-kB essential modulator (NEMO), activation-induced cytidine deaminase and uracil-DNA glycosylase. [61],[62],[63],[64],[65],[66],[67] Addressing different genotypes and phenotypes of HIGM is beyond the scope of this review and was well reviewed by Erdos et al. [60]

Infections dominate this type of immunodeficiency, which involve the upper and lower respiratory tract, commonly caused by Pneumocystis jiroveci pneumonia (PJP). [68] The other most commonly documented clinical manifestations are chronic diarrhea, liver involvement and neutropenia. Lymphoid hyperplasia is also a noteworthy finding in HIGM. [69]

Gastrointestinal manifestations

HIGM patients present frequently with oral ulcers, gingivitis and rectal ulcers, which are probably attributed to neutropenia that commonly complicate HIGM. Fifty percent of HIGM patients experience GI problems, mainly protracted diarrhea, mostly due to infections with Cryptosporidium parvum, Giardia lamblia, Salmonella and Entamoeba histolytica.[68],[69] Other noninfectious causes of diarrhea such as IBD and intestinal nodular bowel disease have been reported. [68]

Liver involvement

Hepatic involvement is a very prominent complication of HIGM. Although sclerosing cholangitis (SC) occurs rarely among children, 10% of these cases are more often associated with primary immunodeficiencies. [70] It is suspected that in sclerosing cholangitis, bile ducts undergo inflammation, which progress to fibrosis leading to cirrhosis and liver failure. C. parvum is the most common pathogen involved in SC. [68]

Malignancy

The exact underlying mechanism for the susceptibility of HIGM patients to biliary tract carcinoma remains elusive. It is hypothesized that long standing cryptosporidium infection may cause epithelium bile duct dysplasia. [71] Hepatitis B, C, and CMV infections were also documented along with autoimmune hepatitis, to possibly progress to hepatocellular carcinoma. SC and malignant tumors of the liver, biliary tree and pancreas are predictors of poor outcome in HIGM. [71]

In conclusion, diarrhea and sclerosing cholangitis are the most prominent findings among children with hyper IgM. Careful monitoring is warranted, especially with cryptosporidium infection, since this pathogen may result in grave consequences.

 IPEX Syndrome



IPEX comprises Immunodeficiency, Polyendocrinopathy, Enteropathy, and occurs as an X-linked Mendelian trait. [72] It is a unique syndrome caused by mutation in FOXP3, a gene encoding putative deoxyribonucleic acid (DNA)-binding protein of the forkhead family, which acts as transcriptional repressor and key modulator of regulatory T cell function. [72],[73],[74],[75] Skin manifestations and other autoimmune phenomena are associated with this syndrome. [74],[75] This rare immunodeficiency confers predisposition to infections commonly with Enterococcus and Staphylococcus. [75]

Gastrointestinal manifestations

The single most common manifestation of IPEX is intractable diarrhea, which was reported in almost all patients. [75] The diarrhea starts very early and may even precede the initiation of feeding of infants, while becoming worse with feeding. Gluten restriction and parenteral nutrition have been found to minimally improve the prognosis. [76] Histopathologic studies of the small intestine reveal severe villous atrophy and mucosal erosion with lymphocytic infiltrates of the submucosa or lamina propria. [77] Failure to thrive usually follows as a result of the enteropathy and malabsorption. [75] Growth retardation has been suspected to start prenatally, which would explain cachexia as a striking feature of this disease. [76] Currently, there is limited information on the disease profile of IPEX and most patients die within the first year of life. Most treatment strategies are directed toward immunosuppression and/or bone marrow transplantation. [78]

 Inflammatory Bowel Disease as a Primary Immunodeficiency



The examples discussed above represent a group of PIDs that may present with GI manifestations. Colitis resembling IBD is an evident example. On the other hand, there is a new concept postulating that IBD, particularly CD, is not considered solely an inflammatory disease but is also a bonafide genetic trait, resulting in an immune defect in the macrophage. It may result from impaired recruitment of granulocytes to the GI wall, causing impaired clearance of the microorganism, and hence contributing to granuloma formation. [79],[80],[81] Over the last 2 decades, the genetic cause of CD remains elusive despite the identification of up to 32 candidate loci in wide genome association studies, among which there is robust association with NOD2/CARD15 gene, encoding the cytosolic receptor that recognizes bacterial peptidoglycans, particularly mycobacterial N-glycolyl muramyl dipeptide. [82],[83] The new hypothesis focuses on impaired macrophage function, caused by a single gene Mendelian defect, rather than polygenic disease. If this is proven to be correct, it will cause a paradigm shift in our understanding of IBD and shall pave the way for major discoveries to delineate genetic causes of CD. [79]

 Conclusion



PIDs have a variety of manifestations, some of which involve the GI and hepatobiliary systems. Infectious and noninfectious GI and hepatic complications pose high risk of morbidity in patients with PIDs. Health care professionals specialized in gastroenterology are not usually involved in the presentation and diagnosis of patients with PIDs. Untrained clinicians may treat these only at the level of its presentation, leaving the PIDs dangerously undiagnosed. Early diagnosis of PIDs and accompanied GI and hepatic complications clearly improve the quality of life for affected patients and allow for appropriate treatments. Multicenter large clinical studies are needed to evaluate the nature of GI and hepatic manifestations in these rare PIDs. Likewise, further studies are needed to evaluate the preventive and therapeutic modalities of PID-associated GI manifestations.

 Acknowledgment



The author thanks Dr. Mosa Fagih, from the Department of Pathology at King Faisal Specialist Hospital, for his valuable comments on the figures of the histopathological findings, and also Dr. Rabih Halwani, from King Saud University, for his valuable editorial comments.

 Abbreviations



PIDs, primary immune deficiency diseases; GI, gastrointestinal; CMV, cytomegalovirus; GvHD, graft versus host disease; CGD, chronic granulomatous disease; AR, autosomal recessive; CD, Crohn's disease; CVID, common variable immunodeficiency; IVIG, intravenous immunoglobulin; HIGM, hyper IgM; IPEX, immunodeficiency, polyendocrinopathy, enteropathy, x-linked; IBD, inflammatory bowel disease.

References

1Woroniecka M, Ballow M. Office evaluation of children with recurrent infection. Pediatr Clin North Am 2000;47:1211-24.
2Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, et al. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007;120:776-94.
3Bonilla FA, Geha RS. 12. Primary immunodeficiency diseases. J Allergy Clin Immunol 2003;111:S571-81.
4Yarmohammadi H, Estrella L, Doucette J, Cunningham-Rundles C. Recognizing primary immune deficiency in clinical practice. Clin Vaccine Immunol 2006;13:329-32.
5Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: Update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol 2006;26:519-32.
6Al-Herz W. Primary immunodeficiency disorders in Kuwait: First report from Kuwait National Primary Immunodeficiency Registry (2004--2006). J Clin Immunol 2008;28:186-93.
7Suliaman FA, Harfi H. High incidence of severe combined immune deficiency in the Eastern Province of Saudi Arabia. Pediatr Asthma Allergy Immunol 2006;19:14-8.
8Suliaman FA, Sheikh S, Almuhsen S, Alsmadi O. Epidemiology of chronic granulomatous disease of childhood in eastern province, Saudi Arabia. Pediatr Asthma Allergy Immunol 2009;22:21-6.
9El Mouzan MI, Al Salloum AA, Al Herbish AS, Qurachi MM, Al Omar AA. Consanguinity and major genetic disorders in Saudi children: A community-based cross-sectional study. Ann Saudi Med 2008;28:169-73.
10Koc I. Prevalence and sociodemographic correlates of consanguineous marriages in Turkey. J Biosoc Sci 2008;40:137-48.
11Rezaei N, Pourpak Z, Aghamohammadi A, Farhoudi A, Movahedi M, Gharagozlou M, et al. Consanguinity in primary immunodeficiency disorders: The report from Iranian Primary Immunodeficiency Registry. Am J Reprod Immunol 2006;56:145-51.
12Hamamy HA, Masri AT, Al-Hadidy AM, Ajlouni KM. Consanguinity and genetic disorders: Profile from Jordan. Saudi Med J 2007;28:1015-7.
13Kanaan ZM, Mahfouz R, Tamim H. The prevalence of consanguineous marriages in an underserved area in Lebanon and its association with congenital anomalies. Genet Test 2008;12:367-72.
14McCabe RP. Gastrointestinal manifestations of non-AIDS immunodeficiency. Curr Treat Options Gastroenterol 2002;5:17-25.
15Agarwal S, Mayer L. Gastrointestinal manifestations in primary immune disorders. Inflamm Bowel Dis 2009 Jul 27. [Epub ahead of print].
16Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of childhood: The clinical, pathological, and laboratory features of a new syndrome. AMA J Dis Child 1959;97:387-408.
17Ochs HD, Edvard SC, Puck JM. Primary immunodeficiency diseases: A molecular and genetic approach. New York, Oxford: Oxford University Press; 1999.
18Landing BH, Shirkey HS. A syndrome of recurrent infection and infiltration of viscera by pigmented lipid histiocytes. Pediatrics 1957;20:431-8.
19Johnston RB Jr. Clinical aspects of chronic granulomatous disease. Curr Opin Hematol 2001;8:17-22.
20Forehand JR, Curnutte JT, Johnston RB Jr. Inherited disorders of phagocytic killing. In: Scriver CR, Sly WS, Valle D, editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995. p. 3995-4026.
21Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000;79:170-200.
22Baehner RL, Kunkel LM, Monaco AP, Haines JL, Conneally PM, Palmer C, et al. DNA linkage analysis of X chromosome-linked chronic granulomatous disease. Proc Natl Acad Sci U S A 1986;83:3398-401.
23Roos D, de Boer M, Kuribayashi F, Meischl C, Weening RS, Segal AW, et al. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 1996;87:1663-81.
24Cross AR, Noack D, Rae J, Curnutte JT, Heyworth PG. Hematologically important mutations: The autosomal recessive forms of chronic granulomatous disease (first update). Blood Cells Mol Dis 2000;26:561-5.
25Heyworth PG, Curnutte JT, Rae J, Noack D, Roos D, van Koppen E, et al. Hematologically important mutations: X-linked chronic granulomatous disease (second update). Blood Cells Mol Dis 2001;27:16-26.
26Matute JD, Arias AA, Wright NA, Wrobel I, Waterhouse CC, Li XJ, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009;114:3309-15 .
27Curnutte JT. Chronic granulomatous disease: The solving of a clinical riddle at the molecular level. Clin Immunol Immunopathol 1993;67:S2-15.
28Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P. NIH conference: Recent advances in chronic granulomatous disease. Ann Intern Med 1983;99:657-74.
29Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease: Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
30Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O'Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004;114:462-8.
31Barton LL, Moussa SL, Villar RG, Hulett RL. Gastrointestinal complications of chronic granulomatous disease: Case report and literature review. Clin Pediatr (Phila) 1998;37:231-6.
32Huang A, Abbasakoor F, Vaizey CJ. Gastrointestinal manifestations of chronic granulomatous disease. Colorectal Dis 2006;8:637-44.
33Al-Muhsen SA, Al-Saud B, Al-Ghonaium A, Al-Mousa H, Al-Dhekri H, Al-Gazlan S, et al, editor. Molecular and clinical profile in a large cohort with chronic granulomatous diseases from Saudi Arabia. Keystone symposium on Human Immunology and Immunodeficiencies. Beijing, China: 2009 May 12 -17 (Oral poster).
34Movahedi M, Aghamohammadi A, Rezaei N, Farhoudi A, Pourpak Z, Moin M, et al. Gastrointestinal manifestations of patients with chronic granulomatous disease. Iran J Allergy Asthma Immunol 2004;3:83-7.
35Johnson FE, Humbert JR, Kuzela DC, Todd JK, Lilly JR. Gastric outlet obstruction due to X-linked chronic granulomatous disease. Surgery 1975;78:217-23.
36Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 2009;104:117-24.
37Schappi MG, Klein NJ, Lindley KJ, Rampling D, Smith VV, Goldblatt D, et al. The nature of colitis in chronic granulomatous disease. J Pediatr Gastroenterol Nutr 2003;36:623-31.
38Hussain N, Feld JJ, Kleiner DE, Hoofnagle JH, Garcia-Eulate R, Ahlawat S, et al. Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology 2007;45:675-83.
39Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 1989;114:555-60.
40Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003;348:2416-22.
41Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990;162:723-6.
42Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994;125:998-1003.
43The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509-16.
44Marciano BE, Wesley R, de Carlo ES, Anderson VL, Barnhart LA, Darnell D, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004;39:692-9.
45Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: A survey of the European experience, 1985-2000. Blood 2002;100:4344-50.
46Gungor T, Halter J, Klink A, Junge S, Stumpe KD, Seger R, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005;79:1596-606.
47Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
48Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep 2004;6:377-83.
49Khodadad A, Aghamohammadi A, Parvaneh N, Rezaei N, Mahjoob F, Bashashati M, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci 2007;52:2977-83.
50Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005;37:829-34.
51Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Drager R, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003;4:261-8.
52Warnatz K, Denz A, Drager R, Braun M, Groth C, Wolff-Vorbeck G, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: A new approach to classify a heterogeneous disease. Blood 2002;99:1544-51.
53Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: Clinical and immunological features of 248 patients. Clin Immunol 1999;92:34-48.
54Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis 1997;8:22-32.
55Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): A clinicopathologic study and review. Am J Surg Pathol 2007;31:1800-12.
56Zullo A, Romiti A, Rinaldi V, Vecchione A, Tomao S, Aiuti F, et al. Gastric pathology in patients with common variable immunodeficiency. Gut 1999;45:77-81.
57Washington K, Stenzel TT, Buckley RH, Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol 1996;20:1240-52.
58Kinlen LJ, Webster AD, Bird AG, Haile R, Peto J, Soothill JF, et al. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet 1985;1:263-6.
59Chiaramonte C, Glick SN. Nodular lymphoid hyperplasia of the small bowel complicated by jejunal lymphoma in a patient with common variable immune deficiency syndrome. AJR Am J Roentgenol 1994;163:1118-9.
60Erdos M, Durandy A, Marodi L. Genetically acquired class-switch recombination defects: The multi-faced hyper-IgM syndrome. Immunol Lett 2005;97:1-6.
61Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-3.
62DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993;361:541-3.
63Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993;361:539-41.
64Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA 2001;98:12614-9.
65Jain A, Ma CA, Liu S, Brown M, Cohen J, Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001;2:223-8.
66Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000;102:565-75.
67Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 2003;4:1023-8.
68Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47-54.
69Quartier P, Bustamante J, Sanal O, Plebani A, Debre M, Deville A, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol 2004;110:22-9.
70Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children. J Pediatr 1994;124:49-56.
71Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997;158:977-83.
72Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
73Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-1.
74Myers AK, Perroni L, Costigan C, Reardon W. Clinical and molecular findings in IPEX syndrome. Arch Dis Child 2006;91:63-4.
75Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003;15:430-5.
76Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002;39:537-45.
77Bennett CL, Ochs HD. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr 2001;13:533-8.
78Baud O, Goulet O, Canioni D, Le Deist F, Radford I, Rieu D, et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001;344:1758-62.
79Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009;206:1839-43.
80Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: An immune deficiency state. Clin Rev Allergy Immunol 2009 in press.
81Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, Sewell GW, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009;206:1883-97.
82Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
83Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.